Nedaplatin (CDGP) is a new anticancer platinum complex, developed in Japan. We studied the toxicities of three compounds, CDGP (n=9), cisplatin (CDDP, n=17), and carboplatin (CBDCA, n=12), when used for FC therapy. Toxicity, including hematotoxicity, gastrointestinal toxicity, and renal toxicity, was evaluated according to the World Health Organization criteria after chemotherapy. In some patients, urinary excretion of N-acetylbeta-D-glucosaminidase (NAG) was also measured. The CDGP group had hematotoxicity, including thrombocytopenia (22%), leukopenia, (56%) and anemia (67%), gastrointestinal toxicity, including nausea and vomiting (67%), and abnormal changes in renal function variables (11%). Gastrointestinal toxicity and nephrotoxicity were mild in the CDGP group. Grade 3 or 4 thrombocytopenia and leukopenia were found in 11% of patients in the CDGP group. Hematotoxicity in the CDGP group was similar to that in the CDDP group and milder than that in the CBDCA group. Gastrointestinal toxicity and nephrotoxicity were similar in the three groups. The maximum NAG index in the CDGP group was similar to that in the CDDP group and higher than that in the CBDCA group. Our results suggest that myelosuppression could be a dose limiting factor in patients receiving combination therapy with 5-Fu and CDGP. Repeated administration of CDGP has an increased risk of nephrotoxicity.
